

1           **A preliminary study on serological assay for severe acute**  
2           **respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238**  
3           **admitted hospital patients**

4  
5   Lei Liu<sup>1\*</sup>, Wanbing Liu<sup>1\*</sup>, Yaqiong Zheng<sup>1</sup>, Xiaojing Jiang<sup>2</sup>, Guomei Kou<sup>1</sup>, Jinya  
6   Ding<sup>3</sup>, Qiongshu Wang<sup>4</sup>, Qianchuan Huang<sup>3</sup>, Yinjuan Ding<sup>1</sup>, Wenxu Ni<sup>1</sup>, Wanlei Wu<sup>1</sup>,  
7   Shi Tang<sup>1</sup>, Li Tan<sup>4</sup>, Zhenhong Hu<sup>2</sup>, Weitian Xu<sup>2</sup>, Yong Zhang<sup>2</sup>, Bo Zhang<sup>2</sup>, Zhongzhi  
8   Tang<sup>2</sup>, Xinhua Zhang<sup>2</sup>, Honghua Li<sup>2</sup>, Zhiguo Rao<sup>2</sup>, Hui Jiang<sup>2</sup>, Xingfeng Ren<sup>2</sup>,  
9   Shengdian Wang<sup>5#</sup>, Shanggen Zheng<sup>1#</sup>

10

11   <sup>1</sup> Department of Transfusion, General Hospital of Central Theater Command of PLA,  
12   Wuhan 430070, Hubei, China

13   <sup>2</sup> Department of Infectious Diseases, General Hospital of Central Theater Command  
14   of PLA, Wuhan 430070, Hubei, China

15   <sup>3</sup> Department of Clinical Laboratory, General Hospital of Central Theater Command  
16   of PLA, Wuhan 430070, Hubei, China

17   <sup>4</sup> Department of Disease Control and Prevention, General Hospital of Central Theater  
18   Command of PLA, Wuhan 430070, Hubei, China

19   <sup>5</sup> CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese  
20   Academy of Sciences, Beijing 100101, China

21

22   \*These authors contributed equally to this work.

23

24   #**Correspondence authors:** Prof Shanggen Zheng MD, Department of Transfusion,  
25   General Hospital of Central Theater Command of PLA, Wuhan 430070, Hubei, China;  
26   **sxkzsg@sina.com** or Prof Shengdian Wang PhD, CAS Key Laboratory of Infection  
27   and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,  
28   China; **sdwang@ibp.ac.cn**

29

30 **Abstract**

31 **Background** The outbreak of the recently emerged novel corona virus disease 2019  
32 (COVID-19) poses a challenge for public health laboratories. We aimed to evaluate  
33 the diagnostic value of serological assay for SARS-CoV-2.

34 **Methods** A newly-developed ELISA assay for IgM and IgG antibodies against N  
35 protein of SARS-CoV-2 were used to screen the serums of 238 admitted hospital  
36 patients with confirmed or suspected SARS-CoV-2 infection from February 6 to  
37 February 14, 2020. SARS-CoV-2 RNA was detected by real time RT-PCR on  
38 pharyngeal swab specimens.

39 **Findings** Of the 238 patients, 194 (81.5%) were detected to be antibody (IgM and/or  
40 IgG) positive, which was significantly higher than the positive rate of viral RNA  
41 (64.3%). There was no difference in the positive rate of antibody between the  
42 confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) whose  
43 nucleic acid tests were negative. After the patients were defined to the different stages  
44 of disease based on the day when the test samples were collected, the analysis results  
45 showed that the antibody positive rates were very low in the first five days after initial  
46 onset of symptoms, and then rapidly increased as the disease progressed. After 10  
47 days, the antibody positive rates jumped to above 80% from less than 50%. On the  
48 contrary, the positive rates of viral RNA kept above 60% in the first 11 days after  
49 initial onset of symptoms, and then rapidly decreased. In addition, half of the  
50 suspected patients with symptoms for 6-10 days were detected to be antibody positive.

51 **Interpretation** The suspected patients were most likely infected by SARS-CoV-2.

52 Before the 11th day after initial onset of symptoms, nucleic acid test is important for  
53 confirmation of viral infection. The combination of serological assay can greatly  
54 improve the diagnostic efficacy. After that, the diagnosis for viral infection should be  
55 majorly dependent on serological assay.

56 **Keywords.** SARS-CoV-2; diagnosis; serological assay; nucleic acid test

57

## 58 Introduction

59 A novel betacoronavirus <sup>1</sup> named severe acute respiratory syndrome coronavirus  
60 2 (SARS-CoV-2) causes a recent cluster cases of respiratory illness named corona  
61 virus disease 2019 (COVID-19) in multiple regions of the world, and it leads to a  
62 serious public health problem especially in Wuhan city, Hubei province, China since  
63 December 2019. <sup>2</sup> By March 1, 2020, more than 80,000 confirmed cases have been  
64 identified globally both in China and other 58 countries spanning Asia, Europe,  
65 Oceania, North and South America, and Northeast Africa. It is evidenced that  
66 SARS-CoV-2 can transmit rapidly from person to person, which is evidently found in  
67 hospital and family settings. <sup>3-5</sup>

68 The SARS-CoV-2 is the seventh member of enveloped RNA coronaviruses  
69 (CoVs). <sup>6-8</sup> Sequence and phylogenetic tree of CoVs analysis indicates that  
70 SARS-CoV-2 is genetically distinct from SARS-CoV and is more closely related to  
71 bat-SL-CoV ZC45 and bat-SL-CoV ZXC21. <sup>1</sup> SARS-CoV-2 owns a similar  
72 receptor-binding domain structure to that of SARS-CoV. <sup>1</sup> A typical CoV contains four  
73 main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N)  
74 proteins. The S protein homotrimers are required for attachment to host receptors, <sup>9</sup>  
75 and both the M protein and the E protein play important roles in virus assembly. <sup>10,11</sup>  
76 The N protein is responsible for packaging the encapsidated genome into virions, <sup>12,13</sup>  
77 and acts as a viral RNA silencing suppressor that is beneficial for the viral replication.  
78 <sup>14</sup> Furthermore, the N protein has high immunogenic activity and is profusely  
79 overexpressed during infection, <sup>15</sup> indicating that N protein should be a potential

80 source of a diagnostic antigen for detecting SARS-CoV-2 infection. Many diagnostic  
81 methods based on the N protein have been developed for SARS-CoV detection.<sup>16-18</sup>  
82 In addition, different CoVs possess special structural and accessory proteins, such as  
83 HE protein, 3a/b protein, and 4a/b protein.<sup>19</sup>

84 Both nucleic acid test and serological assay are commonly used for infectious  
85 disease screening and diagnosis. In the present case of SARS-CoV-2, nucleic acid test  
86 has been being routinely used to detect causative viruses from respiratory secretions  
87 by real-time RT-PCR in China. However, the nucleic acid tests appeared to have a  
88 high false negative rate because of several unavoidable reasons, including the  
89 sensitivity of the detection kits that have not been well assessed, sampling location  
90 and technique, etc. A large number of clinically-suspected patients, whose nucleic  
91 acid tests were negative, are unable to get timely confirmed-diagnosis and hospital  
92 treatment, which potentially promotes the spread of SARS-CoV-2 and leads to a rapid  
93 disease progress of the suspected patients.

94 In this study, a newly-developed IgM and IgG antibody detecting Enzyme-linked  
95 immunosorbent assays (ELISA) based on a recombinant fragment of SARS-CoV-2 N  
96 protein were used to detect IgM and IgG against SARS-CoV-2 in serum of 238  
97 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection. The  
98 results strongly indicated that the suspected patients were infected. We also analyze  
99 the diagnostic value of the IgM and IgG testing in COVID-19, even in the early stage  
100 of disease.

102 **Methods**

103 ***Patients and samples***

104 All consecutive patients (n=238) with confirmed or suspected SARS-CoV-2  
105 infection who have been tested by real-time RT-PCR for viral infection and were  
106 being treated in General Hospital of Central Theater Command of PLA from February  
107 6 to February 14, 2020, were enrolled. The general information (age, sex, vital signs,  
108 coexisting disorders), clinical, laboratory, and radiological characteristics data of the  
109 patients on admission were extracted from electronic medical records. Among the 238  
110 recruited patients, 153 patients were laboratory-confirmed cases, who were tested  
111 positive for viral RNA by real time RT-PCR assay on pharyngeal swab specimens, and  
112 the remaining 85 patients having negative results for real time RT-PCR assay were  
113 clinically diagnosed as highly-suspected cases according to the notice on the issuance  
114 of strategic guidelines for diagnosis and treatment of COVID-19.<sup>20</sup> The serum  
115 samples were collected once from each recruited patient. Meanwhile, the serum  
116 samples from 70 ordinary patients and 50 healthy blood donors were randomly  
117 selected as the controls. The study was approved by the Hospital Ethics Committee  
118 and written informed consent was waived for emerging infectious diseases.

119 ***Real time Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay***

120 Pharyngeal swab specimens were collected from patients and placed into a  
121 collection tube with 200  $\mu$ L of virus preservation solution. Total RNA was extracted  
122 using the respiratory sample RNA isolation kit (Shuoshi, Shanghai, China). After  
123 vortex, 50  $\mu$ L of cell lysates were transferred into another collection tube. The

124 collection tube was centrifugated at 1000 rpm/min for 5 min after standing at room  
125 temperature for 10 minutes. 5  $\mu$ L RNA was prepared and used for real time RT-PCR.  
126 Real time RT-PCR was performed using the nucleic acid testing kit (Daan,  
127 Guangzhou, China) for SARS-CoV-2 detection. The open reading frame 1ab  
128 (*ORF1ab*) and nucleocapsid protein (N) were simultaneously selected as the two  
129 target genes. The human *GAPDH* gene was used as an internal control. The specific  
130 primers and probes set for *ORF1ab* and N were as follows: *ORF1ab*-forward primer  
131 5'-ACCTTCTCTTGCCACTGTAGC-3'; *ORF1ab*-reverse primer  
132 5'-AGTATCAACCATATCCAACCATGTC-3'; and the probe  
133 5'-FAM-ACGCATCACCCAAGTAGCAGGCATAT-BHQ1-3'; N-forward primer  
134 5'-TTCAAGAAATTCAACTCCAG-3'; N-reverse primer  
135 5'-AGCAGCAAAGCAAGAGCAGCATC-3'; and the probe  
136 5'-VIC-TCCTGCTAGAATGGCTGGCAATGGCG-BHQ1-3'. The real time RT-PCR  
137 experiment was thoroughly performed according to kit's instructions. The reaction  
138 mixture contains 17  $\mu$ L of reaction buffer A, 3  $\mu$ L of reaction buffer B, and 5  $\mu$ L RNA  
139 template. The real time RT-PCR assay was performed under the following conditions:  
140 incubation at 50 °C for 15 min and 95 °C for 15 min, 45 cycles of denaturation at  
141 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s. A  
142 cycle threshold value (Ct-value)  $\leq$  40 was defined as a positive test result, and a  
143 Ct-value  $>$  40 was defined as a negative test.

#### 144 ***Enzyme-Linked Immunosorbent Assay (ELISA)***

145 Serological assay was performed using Enzyme-Linked Immunosorbent Assays

146 kit (Lizhu, Zhuhai, China ), which was established for detecting IgM or IgG antibody  
147 against N protein of SARS-CoV-2. For IgM detection, ELISA plates were previously  
148 coated with mouse anti-human IgM ( $\mu$  chain) monoclonal antibody. 100  $\mu$ L diluted  
149 (1:100) serum sample was added into the pre-coated plates with three replicating  
150 wells for each sample and incubated at 37 °C for 1 h. The heat-inactivated positive  
151 and negative serum were included on each plate. After washing, 100  $\mu$ L horse radish  
152 peroxidase (HRP) conjugated recombinant (rN) protein of SARS-CoV-2 was added.  
153 Then the plate was incubated at 37 °C for 30 min followed by washing. 50  $\mu$ L of  
154 TMB substrate solution and 50  $\mu$ L of the corresponding buffer were added and  
155 incubated at 37 °C for 15 min. The reaction was terminated by adding 50  $\mu$ L of 2 M  
156 sulfuric acid, and the absorbance value at 450 nm ( $A_{450}$ ) was determined. The cut off  
157 value was calculated by sum of 0.100 and average  $A_{450}$  of negative control replicates.  
158  $A_{450}$  less than cut off value was defined as a negative test, and  $A_{450}$  greater than or  
159 equal to cut off value was defined as a positive test.

160 For IgG detection , ELISA plates were previously coated with rN protein. 5  $\mu$ L  
161 serum sample diluted with 100  $\mu$ L dilution buffer were added into the plates. After  
162 incubation and washing, HRP-conjugated mouse anti-human IgG monoclonal  
163 antibody was added into the plates for detection. The other operation steps were  
164 performed as described in the above IgM detection. The cut off value was calculated  
165 by the sum of 0.130 and average  $A_{450}$  of negative control replicates.  $A_{450}$  less than cut  
166 off value was defined as a negative test, and  $A_{450}$  greater than or equal to cut off value  
167 was defined as a positive test.



168 ***Statistical analysis***

169 Continuous variables were described as the means and standard deviations or  
170 medians and interquartile ranges (IQR) values. Categorical variables were expressed  
171 as the counts and percentages. Independent group t tests were applied to continuous  
172 variables that were normally distributed; otherwise, the Mann-Whitney test was used.  
173 Categorical variables were compared using the chi-square tests, while the Fisher exact  
174 test was used when the data were limited. Statistical analyses were performed using  
175 Statistical Package for the Social Sciences (SPSS) version 22.0 software. A two-sided  
176  $\alpha$  of less than 0.05 was considered statistically significant.

177

178 **Results**

179 ***Demographics and patient characteristics***

180 The serum samples were collected from 238 admitted hospital patients with  
181 confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater  
182 Command of PLA from February 6 to February 14, 2020. The clinical characteristics  
183 of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65),  
184 and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25  
185 [10.5%]), and cardiovascular disease (24 [10.1%]) were the most common coexisting  
186 disorders. Of these patients, the most common symptoms at illness onset were fever  
187 (206 [86.6%]), dry cough (128 [53.8%]), and fatigue (78 [32.8%]). A small number of  
188 patients possessed the symptoms of abdominal pain (1 [0.4%]), vomiting (3 [1.3%]),  
189 and dizziness (4 [1.7%]). On admission, leucocytes were below the normal range in

190 41 (17.2%) patients and above the normal range in 21 (8.8%) patients. 125 (52.5%)  
191 patients had lymphocytes below the normal range and no patients were found to have  
192 lymphocytes above the normal range. Neutrophils were below the normal range in 28  
193 (11.8%) patients and above the normal range in 32 (13.4%) patients. According to CT,  
194 235 (98.7%) patients showed ground-glass opacity and/or patchy shadowing.

195 According to the positive or negative results of real time RT-PCR assay for  
196 pharyngeal swab specimens, the enrolled patients were divided into two groups: the  
197 confirmed group and the suspected group. There were no statistical differences of  
198 baseline characteristics of the two groups patients.

199 ***Performance and validation of ELISA assays for viral specific IgM and IgG***  
200 ***antibodies***

201 Each serum sample of 238 patients were respectively tested for IgM and IgG  
202 antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N  
203 protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples,  
204 and the positive rate ( 81.5% ) was significantly higher than that of SARS-CoV-2  
205 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A).  
206 Importantly, there were no difference in positive rates of IgM and/or IgG between the  
207 confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85)  
208 (Fig.1B), suggesting that the clinically suspected patients, who were viral RNA  
209 negative detected by RT-PCR, were mostly infected.

210 To verify the specificity of the ELISA assays, the serum samples from 70  
211 randomly-selected ordinary patients and 50 healthy blood donors were simultaneously

212 detected. Four samples from the ordinary patients were identified as antibody positive  
213 (including one dual positive sample, two IgM-positive samples, and one IgG-positive  
214 sample) and no positive was found in the samples of healthy blood donors (Fig.1A).  
215 These results confirmed the specificity of the IgG and IgM ELISA assays.

### 216 *Dynamic analysis of ELISA and RT-PCR assays*

217 To study the diagnostic value of ELISA assay for virus-specific antibodies,  
218 especially in the early stage of the disease, we tried to analyze the positive rates of  
219 ELISA and RT-PCR assays in the different stages of disease. To this end, each patient  
220 was assigned to different days after initial onset of symptoms based on the time when  
221 the pharyngeal swab specimen was detected to be positive or the last recoded  
222 detection was still negative, or the blood was collected. The positive rates of viral  
223 RNA, IgM and/or IgG were compared in every day after initial onset of symptoms  
224 (Table 2). Due to a small number of samples in each individual day, we pooled the  
225 samples in which the positive rates were similar in consecutive days. Thus, the disease  
226 process were divided into five phases of 0-5, 6-10,11-12, 13-15 days and more than  
227 16 days after initial onset of symptoms (Table 3 & Fig.2). The data showed that  
228 positive rates of IgM and/or IgG were very low in the first five days after initial onset  
229 of symptoms because there was no antibody produced in most of patients in this early  
230 stage, and then rapidly increased as the disease progressed. Day 11 after initial onset  
231 of symptoms is a key time point because the positive rates of IgM and/or IgG jumped  
232 to above 80% from less than 50% at this time point. The dynamic pattern is consistent  
233 with SARS-CoV infection.<sup>21</sup> On the contrary, the real-time RT-PCR was more

234 effective for detecting SARS-CoV-2 infection than ELISA in the early stage of disease.  
235 The positive rate of viral RNA detected by RT-PCR was maintained above 60% in the  
236 first 11 days after initial onset of symptoms, and then rapidly decreased with the rapid  
237 increase of positive rate of antibodies. These results demonstrated that ELISA-based  
238 IgM and/or IgG detection should be used as a major viral diagnostic test for the  
239 patients with symptoms for more than 10 days. Because about 50%  
240 clinically-suspected patients with symptoms for 6-10 days were detected to be  
241 positive by ELISA-based IgM and/or IgG detection (Table 4), the combination of  
242 ELISA and RT-PCR assays will greatly improve the detection efficacy, even in the  
243 early stage of COVID-19 infection.

244

## 245 **Discussion**

246 The outbreak of the recently emerged novel coronavirus (SARS-CoV-2) poses a  
247 challenge for public health laboratories, especially for clinical laboratories of the  
248 hospitals in Wuhan, China. Although serological assay is a frequently used method for  
249 viral infection screening and diagnosis, there are few reports about serological assay  
250 in detection of SARS-CoV-2 up to now. In this study, we report the application of the  
251 SARS-CoV-2 N protein-based ELISA for detection of IgM and IgG antibodies in the  
252 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection. The  
253 results showed that the positive rates of IgM and IgG were significantly higher than  
254 that of viral RNA detected by real-time RT-PCR on the pharyngeal swab specimens of  
255 all enrolled patients. This result is further supported by the fact that the suspected

256 patients had the same positive rate of antibody as the confirmed patients. These data  
257 strongly demonstrated that the clinically suspected patients were mostly infected by  
258 SARS-CoV-2.

259 In this study, the serum samples were collected in a time period of 9 days from  
260 the patients in different stages of disease. The positive rates of nucleic acid test and  
261 serological assay in total populations cannot reflect their diagnostic value in  
262 surveillance and control of the disease, because the production of antiviral antibodies  
263 will decrease the positive rates of the nucleic acid test as the disease progresses. In  
264 order to objectively determine the disease stage of the patients, we used the initial  
265 onset of symptoms of the patients as the start time point. Based on the day when the  
266 test sample was collected, all patients were defined to the different stages of disease.  
267 The resulted dynamics patterns of positive rates of viral RNA and antiviral antibodies  
268 proved the rationality of the disease stage definition. Our analysis identified the 11th  
269 day after initial onset of symptoms as a key time point in the disease process when  
270 most infected patients produce antiviral antibodies. After this time point, the diagnosis  
271 for viral infection should majorly depend on serological assay. Before this time point,  
272 nucleic acid test is important for confirmation of viral infection. The combination of  
273 serological assay can greatly improve the diagnostic efficacy.

274 According to the rapid advice guideline for the diagnosis and treatment of  
275 SARS-CoV-2 currently implemented in China,<sup>20</sup> a confirmed case of COVID-19  
276 patients exclusively depends on the positive result of nucleic acid test or virus gene  
277 sequencing. Although this is a preliminary ELISA assay for SARS-CoV-2, our study

278 strongly demonstrate that serological assay is very important for surveillance and  
279 control of the current COVID-19, especially in Wuhan of China, where a lot of  
280 patients are waiting to be confirmed at present. Moreover, most of patients had  
281 symptoms for more than 11 days.

## 282 **Acknowledgements**

283 This work was supported by the National Natural Science Foundation of China  
284 (81801984, 81830003); the National Key Research and Development Program of  
285 China (2019YFC130030); and the China Postdoctoral Science Foundation  
286 (2019M664008). We thank all healthy-care workers involved in this study. We thank  
287 Wuhan Institute of Virology of Chinese Academy of Sciences and Zhuhai Lizhu  
288 Diagnostics Inc. for providing assistance in ELISA detection.

## 289 **Conflict of interest**

290 The authors declare that no conflict of interest exists.

## 291 **Authors' contributions**

292 S.Z., S.W., and L.L. conceived the study and designed experimental procedures;  
293 W.L., Y.Z., W.N., Y.D., W.W., S.T., X.J., J.D., Q.H., Z.H., W.X., Y.Z., B.Z., Z.T.,  
294 X.Z., H.L., Z.R., H.J., and X.R. collected patients' samples. Q.W. and L.T. performed  
295 viral RNA tests. G.K., W.L. W.N., and Y.Z established ELISA and performed  
296 serological assays. S.W., L.L., S.Z., and W.L. wrote the paper. All authors contributed  
297 to data acquisition, data analysis, or data interpretation, and reviewed and approved  
298 the final version.

299

300 **References**

- 301 1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:  
302 implications for virus origins and receptor binding. *Lancet* 2020; published online Jan 30. Doi:  
303 10.1016/S0140-6736(20)30251-8.
- 304 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus  
305 in Wuhan, China. *Lancet* 2020; 395(10223):497-506.
- 306 3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel  
307 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; published online Jan 29. Doi:  
308 10.1056/NEJMoa2001316.
- 309 4. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international  
310 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020;  
311 published online Jan 31. Doi: 10.1016/S0140-6736(20)30260-9.
- 312 5. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel  
313 coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;  
314 395(10223):514-523.
- 315 6. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat Med* 2004;10(12  
316 Suppl):S88-97.
- 317 7. Lee J, Chowell G, Jung E. A dynamic compartmental model for the Middle East respiratory  
318 syndrome outbreak in the Republic of Korea: A retrospective analysis on control interventions and  
319 superspreading events. *J Theor Biol* 2016;408:118-26.
- 320 8. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China,  
321 2019. *N Engl J Med* 2020; 382(8):727-733.
- 322 9. Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope  
323 expression. *J Virol* 1990;64(11):5367-75.
- 324 10. Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus  
325 assembly and morphology. *J Struct Biol* 2011;174(1):11-22.
- 326 11. Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, et al. Severe acute respiratory syndrome  
327 coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. *PLoS*  
328 *Pathog* 2014;10(5):e1004077.
- 329 12. Chang CK, Sue SC, Yu TH, et al. Modular organization of SARS coronavirus nucleocapsid  
330 protein. *J Biomed Sci* 2006;13(1):59-72.
- 331 13. Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine  
332 coronavirus nucleocapsid protein. *J Virol* 2009;83(14):7221-34.
- 333 14. Cui L, Wang H, Ji Y, et al. The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor  
334 of RNA Silencing in Mammalian Cells. *J Virol* 2015;89(17):9029-43.
- 335 15. Narayanan K, Chen CJ, Maeda J, et al. Nucleocapsid-independent specific viral RNA packaging  
336 via viral envelope protein and viral RNA signal. *J Virol* 2003;77(5):2922-7.
- 337 16. Che XY, Qiu LW, Pan YX, et al. Sensitive and specific monoclonal antibody-based capture  
338 enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute  
339 respiratory syndrome. *J Clin Microbiol* 2004;42(6):2629-35.
- 340 17. Guan M, Chen HY, Foo SY, et al. Recombinant protein-based enzyme-linked immunosorbent  
341 assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute  
342 respiratory syndrome (SARS) coronavirus in SARS patients. *Clin Diagn Lab Immunol*

- 343 2004;11(2):287-91.
- 344 18. Woo PC, Lau SK, Wong BH, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and  
345 IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein  
346 in patients with pneumonia due to the SARS coronavirus. *Clin Diagn Lab Immunol* 2004;11(4):665-8.
- 347 19. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis.  
348 *J Med Virol* 2020; 92(4):418-423.
- 349 20. General Office of National Health Committee. Office of State Administration of Traditional  
350 Chinese Medicine. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel  
351 coronavirus (2019-nCoV) infected pneumonia (Fifth edition draft) (2020-02-09) [EB/OL].  
352 <http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-09/12930.html>.
- 353 21. Chen S, Lu D, Zhang M, et al. Double-antigen sandwich ELISA for detection of antibodies to  
354 SARS-associated coronavirus in human serum. *Eur J Clin Microbiol Infect Dis* 2005;24(8):549-53.  
355



356

**Table 1. Demographic and baseline characteristics of 238 enrolled patients**

Characteristics	All patients (N=238)	Confirmed (N=153)	Suspected (N=85)	P value
Age, Median (IQR) – y	55.0 (38.3-65.0)	54.0 (39.0-64.0)	55.0 (38.0-65.0)	0.656
Sex				
Male	138 (58.0%)	93 (60.8%)	45 (52.3%)	0.240
Female	100 (42.0%)	60 (39.2%)	40 (47.6%)	
Vital signs				
Heart rate	89 (80-100)	89 (80-99)	90 (80-104)	0.496
Respiratory rate	18 (18-20)	19 (18-20)	18 (18-20)	0.059
Oxygen saturation	96% (94%-98%)	96% (94%-98%)	97% (95%-98%)	0.292
CT findings of ground-glass opacity and/or patchy shadowing				
opacity and/or patchy shadowing	235/238 (98.7)	151/153 (98.7)	84/85 (98.8)	0.931
Leukocytes ( $\times 10^9$ per L; normal range 3.5-9.5)				
Decreased	41/238 (17.2)	25/153 (16.3)	16/85 (18.8)	0.627
Increased	21/238 (8.8)	16/153 (10.5)	5/85 (5.9)	0.233
Lymphocytes ( $\times 10^9$ per L; normal range 1.1-3.2)				
Decreased	125/238 (52.5)	84/153 (54.9)	41/85 (48.2)	0.324
Neutrophils ( $\times 10^9$ per L; normal range 1.8-6.3)				
Decreased	28/238 (11.8)	17/153 (11.1)	11/85 (12.9)	0.675
Increased	32/238 (13.4)	22/153 (14.4)	10/85 (11.8)	0.571
Signs and symptoms				
Fever	206/238 (86.6)	134/153 (87.6)	72/85 (84.7)	0.533
Dry cough	128/238 (53.8)	86/153 (56.2)	42/85 (49.4)	0.314
Fatigue	78/238 (32.8)	47/153 (30.7)	31/85 (36.5)	0.365
Myalgia	46/238 (19.3)	29/153 (19.0)	17/85 (20.0)	0.845
Dyspnea	44/238 (18.5)	31/153 (20.3)	13/85 (15.3)	0.344
Chill	31/238 (13.0)	20/153 (13.1)	11/85 (12.9)	0.977
Anorexia	29/238 (12.2)	14/153 (9.2)	15/85 (17.6)	0.055
Diarrhea	24/238 (10.1)	14/153 (9.2)	10/85 (11.8)	0.521
Expectoration	21/238 (8.8)	14/153 (9.2)	7/85 (8.2)	0.812
Headache	15/238 (6.3)	12/153 (7.8)	3/85 (3.5)	0.189
Pharyngalgia	14/238 (5.9)	9/153 (5.9)	6/85 (7.1)	0.720
Palpitation	9/238 (3.8)	8/153 (5.2)	1/85 (1.2)	0.120
Chest pain	6/238 (2.5)	4/153 (2.6)	2/85 (2.4)	0.902
Nausea	4/238 (1.7)	2/153 (1.3)	2/85 (2.4)	0.548
Dizziness	4/238 (1.7)	4/153 (2.6)	0/85 (0.0)	0.133
Vomiting	3/238 (1.3)	3/153 (2.0)	0/85 (0.0)	0.194
Abdominal pain	1/238 (0.4)	1/153 (0.7)	0/85 (0.0)	0.455
Coexisting disorders				
Hypertension	63/238 (26.5)	42/153 (27.5)	21/85 (24.7)	0.646

Diabetes	25/238 (10.5)	15/153 (9.8)	10/85 (11.8)	0.636
Cardiovascular disease	24/238 (10.1)	16/153 (10.5)	8/85 (9.4)	0.797
Malignancy	12/238 (5.0)	6/153 (3.9)	6/85 (7.1)	0.289
Cerebrovascular disease	8/238 (3.4)	5/153 (3.3)	3/85 (3.5)	0.915
COPD	3/238 (1.3)	1/153 (0.7)	2/85 (2.4)	0.260

357 Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. P values comparing the  
 358 confirmed patients and the suspected patients are from  $\chi^2$  test, Fisher's exact test, or Mann-Whitney U test. Confirmed=confirmed  
 359 patients. Suspected=suspected patients.

360  
 361  
 362

363 **Table 2. Viral RNA and antibody positive rates of the patients detected each day**  
 364 **from initial onset of symptoms**

Day	Viral RNA <sup>+</sup>	IgM <sup>+</sup> and/or IgG <sup>+</sup>	IgM <sup>+</sup>	IgG <sup>+</sup>	IgM <sup>+</sup> and IgG <sup>+</sup>
0	100.0 (2/2)	50.0 (1/2)	0.0 (0/2)	50.0 (1/2)	0.0 (0/2)
1	83.3 (5/6)	33.3 (1/3)	0.0 (0/3)	33.3 (1/3)	0.0 (0/3)
2	71.4 (5/7)	0.0 (0/3)	0.0 (0/3)	0.0 (0/3)	0.0 (0/3)
3	61.5 (8/13)	25.0 (1/4)	25.0 (1/4)	0.0 (0/4)	0.0 (0/4)
4	69.2 (9/13)	50.0 (2/4)	0.0 (0/4)	0.0 (0/4)	50.0 (2/4)
5	92.3 (12/13)	0.0 (0/1)	0.0 (0/1)	0.0 (0/1)	0.0 (0/1)
6	62.5 (5/8)	60.0 (3/5)	0.0 (0/5)	0.0 (0/5)	60.0 (3/5)
7	88.9 (8/9)	50.0 (2/4)	25.0 (1/4)	0.0 (0/4)	25.0 (1/4)
8	81.8 (18/22)	54.5 (6/11)	18.2 (2/11)	0.0 (0/11)	36.4 (4/11)
9	85.0 (17/20)	42.9 (6/14)	7.1 (1/14)	7.1 (1/14)	28.6 (4/14)
10	75.0 (9/12)	42.9 (3/7)	14.3 (1/7)	0.0 (0/7)	28.6 (2/7)
11	72.2 (13/18)	81.8 (9/11)	18.2 (2/11)	27.3 (3/11)	36.4 (4/11)
12	50.0 (5/10)	80.0 (8/10)	30.0 (3/10)	20.0 (2/10)	30.0 (3/10)
13	44.4 (4/9)	90.9 (10/11)	27.3 (3/11)	9.1 (1/11)	54.5 (6/11)
14	69.2 (9/13)	100.0 (17/17)	29.4 (5/17)	0.0 (0/17)	70.6 (12/17)
15	30.8 (4/13)	90.0 (18/20)	10.0 (2/20)	15.0 (3/20)	65.0 (13/20)
16	50.0 (4/8)	100.0 (16/16)	12.5 (2/16)	25.0 (4/16)	62.5 (10/16)
17	57.1 (4/7)	88.9 (16/18)	0.0 (0/18)	5.6 (1/18)	83.3 (15/18)
18	33.3 (2/6)	100.0 (16/16)	0.0 (0/16)	6.3 (1/16)	93.8 (15/16)
19	33.3 (3/9)	100.0 (19/19)	10.5 (2/19)	21.1 (4/19)	68.4 (13/19)
20	0.0 (0/1)	83.3 (5/6)	0.0 (0/6)	33.3 (2/6)	50.0 (3/6)
>20	36.8 (7/19)	97.2 (35/36)	2.8 (1/36)	8.3 (3/36)	86.1 (31/36)

365 Data are % (n/N). Day= the day after initial onset of symptoms. Viral RNA<sup>+</sup>=a positive result detected by real time RT-PCR.  
 366 IgM<sup>+</sup>=a positive result detected by IgM ELISA and simultaneously a negative result detected by IgG ELISA. IgG<sup>+</sup>=a positive  
 367 result detected by IgG ELISA and simultaneously a negative result detected by IgM ELISA. IgM<sup>+</sup> and IgG<sup>+</sup>=a dual positive result  
 368 detected by IgM and IgG ELISA. IgM<sup>+</sup>and/or IgG<sup>+</sup>=at least a positive result detected by IgM and IgG ELISA.

369  
 370  
 371

372

373

374

375 **Table 3. Viral RNA and antibody positive rates of the patients detected in**  
376 **different stages of disease**

Days	Viral RNA <sup>+</sup>	IgM <sup>+</sup> and/or IgG <sup>+</sup>	IgM <sup>+</sup>	IgG <sup>+</sup>	IgM <sup>+</sup> and IgG <sup>+</sup>
0-5	75.9 (41/54)	29.4 (5/17)	5.9 (1/17)	11.8 (2/17)	11.8 (2/17)
6-10	80.3 (57/71)	48.8 (20/41)	12.2 (5/41)	2.4 (1/41)	34.1 (14/41)
11-12	64.3 (18/28)	81.0 (17/21)	23.8 (5/21)	23.8 (5/21)	33.3 (7/21)
13-15	48.6 (17/35)	93.8 (45/48)	20.8 (10/48)	8.3 (4/48)	64.6 (31/48)
≥16	40.0 (20/50)	96.4 (107/111)	4.5 (5/111)	13.5 (15/111)	78.4 (87/111)
Total	64.3 (153/238)	81.5 (194/238)	10.9 (26/238)	11.3 (27/238)	59.2 (141/238)

377

Data are % (n/N). Days= the day after initial onset of symptoms. Viral RNA<sup>+</sup>=a positive result detected by real time RT-PCR.

378

IgM<sup>+</sup>=a positive result detected by IgM ELISA and simultaneously a negative result detected by IgG ELISA. IgG<sup>+</sup>=a positive

379

result detected by IgG ELISA and simultaneously a negative result detected by IgM ELISA. IgM<sup>+</sup> and IgG<sup>+</sup>=a dual positive result

380

detected by IgM and IgG ELISA. IgM<sup>+</sup>and/or IgG<sup>+</sup>=at least a positive result detected by IgM and IgG ELISA.

381

382

383

384

385

386 **Table 4. Comparison of the antibody positive rates between the confirmed and**  
387 **suspected patients**

	0-5 days	6-10 days	≥11 days
Confirmed	55.6 (5/9)	44.0 (11/25)	93.3 (111/119)
Suspected	0.0 (0/8)	56.3 (9/16)	95.1 (58/61)

388

Data are % (n/N). Confirmed=confirmed patients. Suspected=suspected patients.


389

390

391

392

393



394

395

396

397

398

399

400

401

402

403

404


405

406

407

**Figure 1. Positive rate of viral RNA and antibody in different samples.** A) The positive rate of viral RNA (black column) and antibody (white column) in 238 enrolled patients (two columns on the left), as well as the positive rate of antibody in ordinary patients and healthy donors (two columns on the right). B) Comparison of positive rate of antibody between the laboratory-confirmed (left) and highly-suspected patients (right). Results were compared by chi-square tests.

408



409

410

411 **Figure 2. Dynamics of the positive rate of viral RNA and antibody of the patients**

412 **at the different stages of disease.** The disease courses were divided into five phases

413 of 0-5, 6-10, 11-12, 13-15 days and more than 16 days after initial onset of symptoms.

414 The positive rate of viral RNA (solid circle) and antibody (hollow circle) of the

415 patients at the different phase of disease was shown.

416